US prevalence
~35% of US adults
Source: NHANES 2017-2018
Loading content…
Condition
Metabolic Syndrome
A cluster of conditions — abdominal obesity, hypertension, dyslipidemia, impaired fasting glucose — that raise T2D and CVD risk. No GLP-1 is FDA-approved for the syndrome itself. No GLP-1 is FDA-approved for metabolic syndrome as a discrete diagnosis. Coverage and treatment typically flow through component diagnoses (obesity, T2D, CVD risk). Evidence grade: B (consistent benefit across component endpoints). GLP-1 therapy reliably improves all five NCEP-ATP III metabolic syndrome criteria: waist circumference, triglycerides, HDL, blood pressure, and fasting glucose. STEP 1 secondary analyses showed roughly 50% of subjects met metabolic syndrome criteria at baseline and a substantial fraction resolved on treatment.
Quick answer
UpdatedMetabolic syndrome is a cluster of conditions (central obesity, hypertension, insulin resistance, dyslipidemia) that together increase cardiovascular and diabetes risk. Approximately 35% of US adults have metabolic syndrome. GLP-1 medications address multiple components simultaneously — weight loss, improved insulin sensitivity, reduced blood pressure, improved lipids — making them well-suited for metabolic-syndrome patients with obesity or T2D.
- US prevalence: ~35% of US adults
- NHANES 2017-2018
- Diagnostic criteria: 3 of 5: waist circumference, BP, glucose, triglycerides, HDL
- NCEP ATP III + AHA/NHLBI 2009 harmonized
- CVD risk increase: ~2× CVD events vs general population
- Framingham + multiple cohort studies
- T2D risk increase: ~5× T2D incidence over 5 years
- Multi-cohort analysis
- GLP-1 multi-target effect: Addresses 3-4 of 5 components
- Weight, insulin sensitivity, BP, triglycerides